| Name | Title | Contact Details |
|---|---|---|
Gary Gallant |
Chief Information Officer | Profile |
GEM Health Care Services Inc. is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Great Plains Orthotics and Prosthetics, Inc. is a Ames, IA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. Luke`s, a regional health care system, offers a comprehensive continuum of care serving the 17-county region of northeastern Minnesota, northwestern Wisconsin and the Upper Peninsula of Michigan. The system includes St. Luke`s Hospital in Duluth, Minnesota, Lake View Hospital in Two Harbors, Minnesota, and 11 primary and 27 specialty clinics. Primary care clinics are located in Duluth, Hermantown, Hibbing, Two Harbors, Mountain Iron and Silver Bay, Minnesota, and Ashland and Superior, Wisconsin. Urgent care and Q Care express medical services are also available. St. Luke`s is designated by the American College of Surgeons and the state of Minnesota Department of Health as a Level II trauma center. St. Luke`s Regional Cancer Center offers treatments including Stereotactic Radiosurgery (SRS) and radiation oncology. St. Luke`s Regional Heart Center includes cardiology, cardiothoracic surgery, cardiac rehab services and catheterization lab. Other specialties include obstetrics, gynecology, plastic surgery, pulmonary medicine, allergy, neurosurgery, dermatology, endocrinology, gastroenterology, infectious disease, surgery, occupational health, orthopedics and sports medicine, pediatrics, physical medicine and rehab, rheumatology, psychiatry, urology, hospice and home care. With the University of Minnesota Duluth Medical School, St. Luke`s conducts clinical research in the areas of cancer, lung and heart disease through the Whiteside Institute for Clinical Research.
Active Nutrition is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.